AG 01 - A&G Pharmaceutical
Alternative Names: AG-01 - A&G PharmaceuticalLatest Information Update: 16 Feb 2024
At a glance
- Originator A&G Pharmaceutical
- Developer A&G Pharmaceutical; University of Maryland Greenbaum Cancer Center
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action PC cell-derived growth factor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Mesothelioma; Non-small cell lung cancer; Triple negative breast cancer
Most Recent Events
- 05 Dec 2023 Pharmacodynamics data from a preclinical trial in Triple negative breast cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)
- 14 Apr 2023 US FDA approves IND application for AG 01 in Solid tumours before April 2023
- 14 Feb 2022 Phase-I clinical trials in Mesothelioma (Second-line therapy or greater, Refractory metastatic disease, Late-stage disease) in USA (IV) (NCT05627960)